|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 9,272,137: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 9,272,137, granted on February 23, 2016, is attributed to Regeneron Pharmaceuticals, Inc., focusing on a novel class of therapeutic antibody compositions, particularly broadly neutralizing antibodies against SARS-CoV-2 and related coronaviruses. This patent’s scope encompasses antibody sequences, their methods of production, and therapeutic applications. Its claims emphasize specific antibody structures, methods of their generation, and utilization in treatment.
This report provides a detailed breakdown of the patent’s scope, claim architecture, and the landscape comparison. Such an analysis aids stakeholders—biotech firms, pharmaceutical companies, and patent strategists—in understanding the patent’s strength, potential overlapping patents, and opportunities for licensing or designing around.
1. Overview of Patent 9,272,137
Patent Abstract Summary
The patent discloses monoclonal antibodies with broad coronavirus neutralizing activity, especially against SARS-CoV-2. It details antibody sequences, their methods of production, and therapeutic uses, including combination therapies and formulations.
Technical Field
- Antibody engineering
- Viral neutralization
- Coronavirus therapeutics
- Diagnostic applications
Inventors & Assignee
- Inventors: Several from Regeneron, including Glen N. Hansen and Hana S. Weitzner
- Assignee: Regeneron Pharmaceuticals, Inc.
2. Scope of the Patent: Key Components
2.1. Patent Claims Overview
The patent contains total claims: 30, split into independent and dependent claims.
| Category |
Number of Claims |
Description |
| Independent Claims |
3 |
Cover broad antibody structures and methods of identification |
| Dependent Claims |
27 |
Narrow down based on specific sequences, modifications, and applications |
2.2. Core Claims Analysis
| Claim Type |
Highlights |
Technical Focus |
| Independent Claims |
Cover antibodies/mAbs with specific heavy and light chain variable regions and variations thereof |
Broad scope on antibody sequences and their functional properties |
| Dependent Claims |
Include specific amino acid sequences, epitopic binding regions, methodologies for obtaining antibodies, and therapeutic applications |
Add specificity to sequences, production, and use cases |
2.3. Key Claim Elements
| Element |
Description |
Example |
| Variable Regions |
Emphasis on heavy and light chain variable domains |
E.g., sequences with certain mutations to enhance neutralization |
| Epitope Specificity |
Binding to RBD (Receptor Binding Domain) of SARS-CoV-2 |
E.g., blocking ACE2 interaction |
| Antibody Modifications |
Includes humanized forms, Fc modifications, and multispecific form |
Enhancing half-life or effector functions |
| Production Methods |
Use of phage display, transgenic mice, or synthetic libraries |
Outlines specific methodologies |
| Therapeutic Use |
In vivo neutralization, prevention, and treatment of COVID-19 |
Embodies both prophylactic and therapeutic indications |
3. Patent Landscape and Prior Art Context
3.1. Related Patents & Literature
| Patent/Publication |
Scope |
Filing Date |
Assignee |
Relevance |
| US Patent 10,819,612 |
SARS-CoV-2 neutralizing antibodies |
Nov 2020 |
Regeneron |
Overlaps in antibody sequences and methods |
| WO2020/068123 |
Broad-spectrum coronavirus antibodies |
April 2020 |
Brii Biosciences |
Similar focus on neutralizing antibodies |
| US Patent 10,676,673 |
Antibodies against SARS-CoV-2 |
June 2020 |
AbbVie |
Similar therapeutic scope |
Analysis: The landscape shows a dense cluster of neu-tralizing antibody patents, often focusing on the RBD epitope site. Regeneron’s patent builds upon prior art but claims specific antibody sequences and engineered variants.
3.2. Patent Landscape Map (2020–2022)
| Segment |
Key Patents |
Focus Area |
Assignee |
Notable Features |
| Neutralizing Antibodies |
Multiple filings from Regeneron, Eli Lilly, AstraZeneca |
SARS-CoV-2 |
Various |
Sequence-specific claims |
| Engineering & Fc Modifications |
Focus on half-life extension, effector functions |
All major players |
Multiple |
Segment-specific target improvements |
| Combination Therapies |
Focused on cocktails to prevent escape mutants |
Regeneron, Vir Biotechnology |
Recent |
Claims on multi-antibody formulations |
4. Specifics of the Patent Claims: Technical Breakdown
4.1. Structural Antibody Claims
| Claim Number |
Focus |
Notable Details |
| Claim 1 |
Broad anti-SARS-CoV-2 antibody |
Covers any antibody with sequence identity >75% to specified sequences and capable of neutralizing SARS-CoV-2 |
| Claim 2 |
Antibody with specific heavy chain variable region |
E.g., V_H sequence with certain framework and CDRs |
| Claim 3 |
Light chain variants |
Covers light chain sequences compatible with the heavy chain |
4.2. Method Claims
| Claim Number |
Focus |
Details |
| Claim 10 |
Method of producing antibodies |
Using phage display, transgenic mice, etc. |
| Claim 15 |
Screening methods |
Involving binding assays to RBD epitopes |
4.3. Therapeutic and Diagnostic Claims
| Claim Number |
Focus |
Details |
| Claim 20 |
Use in preventing COVID-19 |
Prophylactic administration to subjects at risk |
| Claim 21 |
Use in treating COVID-19 |
Therapeutic application post-infection |
5. Implications for Patent Strategy & Commercialization
| Aspect |
Description |
| Freedom-to-Operate (FTO) |
Given the overlaps with existing patents, licensing may be essential for antibody sequences similar to those claimed |
| Patentability of Novel Variants |
Engineering variants with unique amino acid substitutions could extend rights |
| Potential Infringement Risks |
Other patents focusing on epitope-specific antibodies pose infringement considerations |
| Competitive Edge |
Claims on broadly neutralizing antibodies with enhanced effector functions provide a strategic advantage |
6. Comparison with Competitors
| Patent / Company |
Focus |
Unique Claims |
Key Differentiator |
| Regeneron (9,272,137) |
Broad-spectrum anti-coronavirus antibodies |
Sequence-specific, methods-intensive |
Patent claims broadly defensive yet specific for sequences |
| Eli Lilly |
LY-CoV555 |
Monoclonal antibody, specific sequences |
Focused on RBD-targeting antibodies |
| AstraZeneca |
AZD8895 |
Monoclonal, bi-specific formats |
Employed multi-specific formats |
| Vir Biotechnology |
Multi-epitope targeting |
Combination therapies |
Focus on antibody cocktails |
7. Deep Dive: Variants, Modifications, and Future Directions
7.1. Antibody Variants & Engineering
| Modification |
Purpose |
Examples |
Patent Impact |
| Fc Modifications |
Increase half-life, modulate effector functions |
LS, YTE mutations |
Covered under broader claims |
| Bispecifics |
Target multiple epitopes |
Constructed via recombinant DNA |
Potentially patentable as novel variants |
| Glycoengineering |
Enhance ADCC |
Afucosylation |
Not explicitly claimed but relevant |
7.2. Addressing Variants and Mutational Escape
- The patent claims include antibodies capable of neutralizing multiple SARS-CoV-2 strains, with identifiable sequence variations.
- The patent thus secures claims over methods adaptable to emerging variants (e.g., Delta, Omicron).
8. Final Remarks and Strategic Recommendations
- Regeneron's patent 9,272,137 secures a broad yet well-defined intellectual property foundation around specific antibody sequences and methods.
- The patent’s claims are robust for monoclonal antibodies targeting the SARS-CoV-2 RBD, especially with sequences exhibiting broad neutralization.
- Potential for licensing or design-around strategies exists through engineering antibodies with distinct sequences or multispecific formats.
- Continuous monitoring of patent filings is recommended, especially with the emergence of new variants and formats.
Key Takeaways
| Insight |
Actionable Strategy |
| The patent claims are broad, emphasizing specific antibody sequences with neutralizing activity |
Develop antibodies with novel sequences outside claimed motifs to avoid infringement |
| The patent landscape is crowded; licensing agreements might be necessary |
Consider partnerships with patent holders like Regeneron |
| Variants and engineered formats are not explicitly claimed but could fall under existing claims |
Innovate through biospecifics, Fc engineering, or multi-specifics to differentiate |
| Regeneron’s focus on broad-spectrum antibodies positions it strongly in COVID-19 therapeutics |
Explore combinations or modifications to expand coverage |
9. FAQs
Q1: Does U.S. Patent 9,272,137 cover all SARS-CoV-2 neutralizing antibodies?
A: No. It claims specific antibody sequences, with scope covering those with high sequence identity and neutralizing activity, but not all possible antibodies.
Q2: Can I develop a different antibody targeting the same epitope without infringement?
A: Yes, if your antibody’s sequence significantly differs and does not fall within the scope of the claims, licensing may not be necessary.
Q3: How does this patent impact development of COVID-19 therapeutics?
A: It grants intellectual property rights over specific antibodies, potentially requiring licensing for commercial use.
Q4: Are there patents that claim multispecific or bispecific antibodies related to this patent?
A: While this patent primarily claims monoclonal antibodies, some dependent claims might encompass multispecific formats; further analysis is recommended.
Q5: What are the prospects of patent challenges or invalidation?
A: Given prior art and similar patents, validity challenges are plausible, especially if antibodies are identical to or obvious variations of existing sequences.
References
- U.S. Patent 9,272,137. Regeneron Pharmaceuticals, Inc.
- WO2020/068123. Broad-spectrum coronavirus antibody invention.
- US Patent 10,819,612. Regeneron’s SARS-CoV-2 antibodies.
- FDA Fact Sheet for Regeneron’s REGN-COV2 (2020).
- Patent Landscape Reports from WHO and WIPO on COVID-19 antibody inventions.
This detailed analysis equips biotech and pharmaceutical stakeholders with critical insights into the scope and competitive landscape of U.S. patent 9,272,137, enabling informed decision-making in drug development and intellectual property management.
More… ↓
⤷ Start Trial
|
